Stocktoria
EUPRAXIA PHARMACEUTICALS INC. EPRX
EUPRAXIA PHARMACEUTICALS INC. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — |
| R&D expense | $21.3M | $16.1M | $20.4M | $13.6M |
| Interest expense | $0 | $603,573 | $1.2M | $982,856 |
| Income tax | $19,091 | $1,804 | $36,423 | $0 |
| Net income | -$38.6M | -$25.5M | -$28.2M | -$18.5M |
| EPS (diluted) | $-1.03 | $-0.76 | $-1.17 | $-0.96 |
| Operating cash flow | -$28.6M | -$30.0M | -$20.7M | -$14.4M |
| Cash & equivalents | $80.6M | $33.1M | $19.3M | $18.3M |
| Total assets | $86.2M | $34.9M | $20.3M | $19.1M |
| Total liabilities | $5.7M | $3.1M | $19.4M | $11.9M |
| Shareholders' equity | $82.0M | $33.4M | $2.2M | $7.8M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.